Cats and dogs could get fat jabs
Veterinary equivalents of drugs such as Wegovy and Mounjaro are being developed and tested by boffins and could be delivered to canines and felines via implants.
Early clinical trials in cats have revealed that small doses of the drug exenatide - which works similarly to the anti-obesity medication semaglutide - are effective when it comes to reducing the calorie intake and body weight of animals.
A trial last year fitted five moggies with an experimental implant known as OKV-119, which released the chemical into the animal's blood for 84 days.
Analysis revealed that four of five cats had a reduction in body mass of at least five per cent.
The trial is now being extended to dogs in a partnership with drug companies Okava and Vivani and the medication could be available as early as 2028 should it be successful.
Michael Klotsman, the chief executive of Okava, told The Guardian newspaper: "What owners should expect to see is their pet eating appropriate portions without the previous food obsession - they'll still eat regularly and show interest in meals, just without the excess begging, scavenging or gulping behaviour."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Perth Now
a day ago
- Perth Now
Cats and dogs could get fat jabs
Weight-loss jabs could soon be administered to cats and dogs. Veterinary equivalents of drugs such as Wegovy and Mounjaro are being developed and tested by boffins and could be delivered to canines and felines via implants. Early clinical trials in cats have revealed that small doses of the drug exenatide - which works similarly to the anti-obesity medication semaglutide - are effective when it comes to reducing the calorie intake and body weight of animals. A trial last year fitted five moggies with an experimental implant known as OKV-119, which released the chemical into the animal's blood for 84 days. Analysis revealed that four of five cats had a reduction in body mass of at least five per cent. The trial is now being extended to dogs in a partnership with drug companies Okava and Vivani and the medication could be available as early as 2028 should it be successful. Michael Klotsman, the chief executive of Okava, told The Guardian newspaper: "What owners should expect to see is their pet eating appropriate portions without the previous food obsession - they'll still eat regularly and show interest in meals, just without the excess begging, scavenging or gulping behaviour."
The Age
2 days ago
- The Age
Ozempic maker cuts price of wonder drug in half in US
Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices. Patients can now get Ozempic for $US499 ($768) a month — about half of its US list price — through Novo's cash-pay pharmacy NovoCare, the company said in a statement on Monday. It's also partnering with GoodRx Holdings to offer Ozempic and its sister weight-loss drug Wegovy for the same price at pharmacies across the US. President Donald Trump has been putting pressure on pharmaceutical companies to lower prices, including sending letters to drugmakers like Novo demanding action. The Biden administration previously attempted to get Novo to lower the price of Ozempic, the Danish company's best-selling drug, without success. Novo said the offer is unrelated to its discussions with the US government. It comes less than a week after weight-loss rival Eli Lilly & Co. made its own adjustment, raising the list price for its obesity shot in the UK by as much as 170 per cent. Still, it's not yet clear how much difference either measure will make when it comes to variations in what patients actually pay across countries. Novo's shares gained as much as 7.8 per cent to a session high following the announcement. The stock was already advancing on Monday after Wegovy received Food and Drug Administration approval to treat a serious form of liver disease. The news also sent GoodRx's stock up 39 per cent, its biggest intraday jump since September 2020. GoodRx Chief Executive Officer Wendy Barnes said the partnership with Novo makes it much easier for patients to get a more affordable version of the drugs. 'We are the number one branded marketplace to seek cash pricing on brands and generics, so for that reason we already have the millions of consumers searching for these types of products,' Barnes said in an interview with Bloomberg TV. 'This is where they are looking for the most affordable price and the ability to access them.' Novo first started selling Wegovy directly to consumers in March, following Lilly's earlier example. Both drugmakers have been contending with the widespread use of less expensive, copycat versions of their shots — known as compounded drugs — that became popular during supply shortages.
Sydney Morning Herald
2 days ago
- Sydney Morning Herald
Ozempic maker cuts price of wonder drug in half in US
Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices. Patients can now get Ozempic for $US499 ($768) a month — about half of its US list price — through Novo's cash-pay pharmacy NovoCare, the company said in a statement on Monday. It's also partnering with GoodRx Holdings to offer Ozempic and its sister weight-loss drug Wegovy for the same price at pharmacies across the US. President Donald Trump has been putting pressure on pharmaceutical companies to lower prices, including sending letters to drugmakers like Novo demanding action. The Biden administration previously attempted to get Novo to lower the price of Ozempic, the Danish company's best-selling drug, without success. Novo said the offer is unrelated to its discussions with the US government. It comes less than a week after weight-loss rival Eli Lilly & Co. made its own adjustment, raising the list price for its obesity shot in the UK by as much as 170 per cent. Still, it's not yet clear how much difference either measure will make when it comes to variations in what patients actually pay across countries. Novo's shares gained as much as 7.8 per cent to a session high following the announcement. The stock was already advancing on Monday after Wegovy received Food and Drug Administration approval to treat a serious form of liver disease. The news also sent GoodRx's stock up 39 per cent, its biggest intraday jump since September 2020. GoodRx Chief Executive Officer Wendy Barnes said the partnership with Novo makes it much easier for patients to get a more affordable version of the drugs. 'We are the number one branded marketplace to seek cash pricing on brands and generics, so for that reason we already have the millions of consumers searching for these types of products,' Barnes said in an interview with Bloomberg TV. 'This is where they are looking for the most affordable price and the ability to access them.' Novo first started selling Wegovy directly to consumers in March, following Lilly's earlier example. Both drugmakers have been contending with the widespread use of less expensive, copycat versions of their shots — known as compounded drugs — that became popular during supply shortages.
